

Form PTO-1449 (modified)		Atty. Docket No. DFCI:005US	Serial No. 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2004/0018181	01/29/04	Kufe <i>et al.</i>	424	93.21	05/29/03
	A2	5,380,712	01/10/95	Ballance <i>et al.</i>	514	12	02/14/92
	A3	5,766,883	06/16/98	Ballance and Goodey	435	69.7	11/17/93
	A4	5,965,386	10/12/99	Kerry-Williams <i>et al.</i>	435	69.1	03/01/95

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	WO 00/25827	05/11/00	WIPO	English
	B2	WO 01/57068	08/09/01	WIPO	English
	B3	WO 03/088995	10/30/03	WIPO	English
	B4	WO 2004/044160	05/27/04	WIPO	English
	B5	WO 96/03502	02/08/96	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	"MUC-1/X mucin short variant," GenBank Accession No.: AAD10856, dated June 5, 2001
	C2	"MUC-1/Z mucin short variant," GenBank Accession No.: AAD10858, dated June 5, 2001.
	C3	"Mucin 1 precursor, non-repetitive splice from Y [validated] – human," GenBank Accession No.: S48146, dated April 20, 2000.
	C4	Backstrom <i>et al.</i> , "Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells," <i>Biochemical J.</i> , 376:677-686, 2003.
	C5	Barrett <i>et al.</i> , "PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?," <i>Int. J. Cancer</i> , 101:581-588, 2002.

25699980.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. DFCI:005US	Serial No. 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C6	Baruch <i>et al.</i> , "Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function," <i>Int. J. Cancer</i> , 71:741-749, 1997.
	C7	Cunningham <i>et al.</i> , "Calreticulin binding and other biological activities of survival peptide Y-P30 including effects of systemic treatment of rats," <i>Exp. Neurol.</i> , 163:457-468, 2000.
	C8	Cunningham <i>et al.</i> , "Identification of a survival-promoting peptide in medium conditioned by oxidatively stressed cell lines of nervous system origin," <i>J. Neurosci.</i> , 18:7047-7060, 1998.
	C9	Cunningham <i>et al.</i> , "Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells," <i>Exp. Neurol.</i> , 177:32-39, 2002.
	C10	Elbashir <i>et al.</i> , "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213, 2002.
	C11	Gendler <i>et al.</i> , "A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats," <i>J Biol Chem</i> , 263:12820-12823, 1988.
	C12	Julian and Carson, "Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells," <i>Biochem. Biophys. Res. Commun.</i> , 293:1183-1190, 2002.
	C13	Kufe <i>et al.</i> , "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors," <i>Hybridoma</i> , 3:223-232, 1984.
	C14	Li <i>et al.</i> , "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein," <i>Mol Cancer Res</i> , 1:765-775, 2003.
	C15	Li <i>et al.</i> , "Human DF3/MUC1 carcinoma-associated protein functions as an oncogene," <i>Oncogene</i> , 22:6107-6110, 2003.
	C16	Li <i>et al.</i> , "Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin," <i>Mol Cell Biol</i> , 18:7216-7224, 1998.
	C17	Li <i>et al.</i> , "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin," <i>J Biol Chem</i> , 276:6061-6064, 2001.
	C18	Li <i>et al.</i> , "The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin," <i>J Biol Chem</i> , 276:35239-35242, 2001.
	C19	Ligtenberg <i>et al.</i> , "Suppression of cellular aggregation by high levels of episialin," <i>Cancer Res</i> , 52:2318-2324, 1992.

25699980.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. DFCI:005US	Serial No. 10/577,003
List of Patents and Publications for Applicant's		Applicant Surender KHARBANDA Donald W. KUFE	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C20	Obermair <i>et al.</i> , "Expression of MUC1 splice variants in benign and malignant ovarian tumours," <i>Int. J. Cancer.</i> , 100:166-171, 2002.
	C21	Oosterkamp <i>et al.</i> , "Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z)," <i>Int. J. Cancer</i> , 72:87-94, 1997.
	C22	Parry <i>et al.</i> , "Identification of MUC1 proteolytic cleavage sites in vivo," <i>Biochem. Biophys. Res. Commun.</i> , 283:715-720, 2001.
	C23	Porter <i>et al.</i> , "A neural survival factor is a candidate oncogene in breast cancer," <i>Proc. Natl. Acad. Sci. USA</i> , 100:10931-10936, 2003.
	C24	Ren <i>et al.</i> , "Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents," <i>Cancer Cell</i> , 5, 163-175, 2004.
	C25	Ren <i>et al.</i> , "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling," <i>J Biol Chem</i> , 277:17616-17622, 2002.
	C26	Schroeder <i>et al.</i> , "Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland," <i>J Biol Chem</i> , 276:13057-13064, 2001.
	C27	Siddiqui <i>et al.</i> , "Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen," <i>Proc Natl Acad Sci USA</i> , 85:2320-2323, 1988.
	C28	Yamamoto <i>et al.</i> , "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion," <i>J Biol Chem</i> , 272:12492-12494, 1997.
	C29	Yeh <i>et al.</i> , "Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate," <i>Proc. Natl. Acad. Sci. USA</i> , 89:1904-1908, 1992.
	C30	Zrihan-Licht <i>et al.</i> , "Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue," <i>Eur. J. Biochem.</i> , 224:787-795, 1994.

25699980.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.